SEARCH:   Advanced

Blood, 15 February 2008, Vol. 111, No. 4, pp. 1862-1865. Prepublished online as a Blood First Edition Paper on November 20, 2007; DOI 10.1182/blood-2007-09-112953. This Article Full Text (PDF) All Versions of this Article: blood-2007-09-112953v1 111/4/1862    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Vener, C. Articles by Lambertenghi Deliliers, G. Search for Related Content PubMed PubMed Citation Articles by Vener, C. Articles by Lambertenghi Deliliers, G. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted September 19, 2007 Accepted October 30, 2007 Prognostic implications of the European consensus for grading of bone marrow fibrosis in chronic idiopathic myelofibrosis (CIMF) Claudia Vener*, Nicola Stefano Fracchiolla, Umberto Gianelli, Rossella Calori, Franca Radaelli, Alessandra Iurlo, Sabrina Caberlon, Giancarla Gerli, Leonardo Boiocchi, and Giorgio Lambertenghi Deliliers Ematologia I, Centro Trapianti di Midollo, University of Milan, Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Milan, Italy II Cattedra di Anatomia Patologica, DMCO, A. O. San Paolo, University of Milan, Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Milan, Italy Divisione di Ematologia, Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Milan, Italy Unita di Ematologia e Trombosi, Ospedale San Paolo; DMCO, University of Milan, Milano, Italy * Corresponding author; email: claudiavener{at}tiscali.it. Various clinical prognostic scoring systems (PSSs) have been suggested as means of selecting high-risk chronic idiopathic myelofibrosis (CIMF) patients at diagnosis. The WHO has recently proposed strict diagnostic criteria for CIMF, and the European consensus for bone marrow fibrosis (BMF) grading recommends four classes. It has been suggested that BMF grading may play a prognostic role in CIMF, but it has never been compared with the other PSSs in the same patients. We tested a prognostic model for overall survival (OS) based on the WHO criteria and BMF grading in 113 consecutive patients with chronic myeloproliferative disorders (98 with CIMF and 15 with post-polycythemic myelofibrosis), and compared the findings with those of PSSs. The results showed that our model is significantly associated with different OS and, unlike the other PSSs, clearly discriminates the OS of intermediate- and high-risk patients. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: J. Thiele Philadelphia Chromosome-Negative Chronic Myeloproliferative Disease Am J Clin Pathol, August 1, 2009; 132(2): 261 - 280. [Abstract] [Full Text] [PDF] C. Tripodo, A. Di Bernardo, M. P. Ternullo, C. Guarnotta, R. Porcasi, S. Ingrao, U. Gianelli, E. Boveri, E. Iannitto, G. Franco, et al. CD146+ bone marrow osteoprogenitors increase in the advanced stages of primary myelofibrosis Haematologica, January 1, 2009; 94(1): 127 - 130. [Abstract] [Full Text] [PDF]

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020